Search
Vestipitant
go.drugbank.com/drugs/DB11949InvestigationalVestipitant has been investigated for the treatment of Tinnitus.
Categories: Heterocyclic Compounds, 1-Ring, Neurokinin-1 Receptor AntagonistsLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalbeginning of a new wave of treatment options for patients suffering from insomnia. … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalcan produce a broad adaptative and innate immune cell inhibitory activity. … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. … [L2927] _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalHowever, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersNaquotinib
go.drugbank.com/drugs/DB12036InvestigationalNaquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations,...
Categories: Heterocyclic Compounds, 1-RingLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: PREVYMİS 240 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, PREVYMİS 480 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET